Logo
x

Search category

Subscribe Now

HUTCHMED

HUTCHMED Reports P-III Trial (ESLIM-01) Results of Sovleplenib for Primary Immune Thrombocytopenia in China

HUTCHMED Reports P-III Trial (ESLIM-01) Results of Sovleplenib for Primary Immune Thrombocytopenia in China

  • August 21, 2023
HUTCHMED Receives the NMPA’s Breakthrough Therapy Designation for Fruquintinib + Sintilimab to Treat Advanced Endometrial Cancer

HUTCHMED Receives the NMPA’s Breakthrough Therapy Designation for Fruquintinib + Sintilimab to Treat Advanced Endometrial Cancer

  • July 20, 2023
HUTCHMED Initiates the P-I Study of HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED Initiates the P-I Study of HMPL-415 for Advanced Malignant Solid Tumors in China

  • July 10, 2023
HUTCHMED Reports the Completion of Patient Enrollment of Amdizalisib in P-II Registration Trial for Follicular Lymphoma in China

HUTCHMED Reports the Completion of Patient Enrollment of Amdizalisib in P-II Registration Trial for Follicular Lymphoma in China

  • February 27, 2023
HUTCHMED Entered into an Exclusive License Agreement with Takeda to Develop and Commercialize Fruquintinib

HUTCHMED Entered into an Exclusive License Agreement with Takeda to Develop and Commercialize Fruquintinib

  • January 23, 2023
HUTCHMED Completes Patient Enrolment of P-III (ESLIM-01) for Primary Immune Thrombocytopenia Patients in China

HUTCHMED Completes Patient Enrolment of P-III (ESLIM-01) for Primary Immune Thrombocytopenia Patients in China

  • January 3, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.